Skip to main content

Interpace Diagnostics Thyroid Assays Covered In-Network by Blue Shield of California

NEW YORK – Interpace Diagnostics said today that it has signed a contract with Blue Shield of California to cover its ThyGeNext and ThyraMir thyroid cancer detection assays as an in-network service, which will limit members' out-of-pocket expenses. 

Blue Shield of California, a member of the Blue Cross Blue Shied Association that covers about four million individuals, had said in March of 2018 that it would cover the two tests. 

According to Interpace, the ThyGeNext-ThyraMir combination uses next-generation sequencing of a patient's DNA and RNA along with a micro-RNA classifier to provide physicians with actionable test results.

"Adding Blue Shield of California under contract and as an in-network provider … represents another milestone in solidifying our molecular thyroid products' place in the market," Interpace CEO Jack Stover said in a statement. 

Interpace said in June that Pennsylvania-based Independence Blue Cross agreed to cover its thyroid tests.